Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Videos|July 14, 2020
COVID-19 in the ICU: A Cardiothoracic Surgeon's Experience
Author(s)Grace Halsey
Cardiothoracic surgeon Brian Lima, MD spent weeks in a large metropolitan New York City ICU treating the sickest patients with COVID-19. He shares details.
Advertisement
Brian Lima, MD, director of heart transplant surgery at North Shore University Hospital in New York, turned over his ICU, the hospital's largest, to COVID-19 patients and, like physicians from all over the institution, became a COVID-19 doctor for more than a month. This is what he saw.
Dr Lima is the surgical director of heart transplantation at North Shore University Hospital in Manhasset, New York, and is associate professor of cardiovascular and thoracic surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. @BrianLimaMD
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement